Accéder au contenu
Merck

Identification of Tn antigen O-GalNAc-expressing glycoproteins in human carcinomas using novel anti-Tn recombinant antibodies.

Glycobiology (2019-11-20)
Yasuyuki Matsumoto, Matthew R Kudelka, Melinda S Hanes, Sylvain Lehoux, Sucharita Dutta, Mark B Jones, Kathryn A Stackhouse, Gabrielle E Cervoni, Jamie Heimburg-Molinaro, David F Smith, Tongzhong Ju, Elliot L Chaikof, Richard D Cummings
RÉSUMÉ

The Tn antigen is a neoantigen abnormally expressed in many human carcinomas and expression correlates with metastasis and poor survival. To explore its biomarker potential, new antibodies are needed that specifically recognize this antigen in tumors. Here we generated two recombinant antibodies to the Tn antigen, Remab6 as a chimeric human IgG1 antibody and ReBaGs6 as a murine IgM antibody and characterized their specificities using multiple biochemical and biological approaches. Both Remab6 and ReBaGs6 recognize clustered Tn structures, but most importantly do not recognize glycoforms of human IgA1 that contain potential cross-reactive Tn antigen structures. In flow cytometry and immunofluorescence analyses, Remab6 recognizes human cancer cell lines expressing the Tn antigen, but not their Tn-negative counterparts. In immunohistochemistry (IHC), Remab6 stains many human cancers in tissue array format but rarely stains normal tissues and then mostly intracellularly. We used these antibodies to identify several unique Tn-containing glycoproteins in Tn-positive Colo205 cells, indicating their utility for glycoproteomics in future biomarker studies. Thus, recombinant Remab6 and ReBaGs6 are useful for biochemical characterization of cancer cells and IHC of tumors and represent promising tools for Tn biomarker discovery independently of recognition of IgA1.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Tn Antigen, ≥99.0% (TLC)